Forbion Capital Partners, a Dutch life-sciences venture capital firm, announces today that it has led the closing of a CAD 13.5 million (EUR 9.6 million) series B financing round for enGene, Inc. with a syndicate of leading life-science investors. Sander van Deventer from Forbion Capital Partners has joined the enGene Board of Directors.